OXBDF (Oxford BioMedica) Stock Based Compensation: $6.3 Mil (TTM As of Dec. 2025)


OXBDF Oxford BioMedica PLC OXBDF
71 GF Score
Price $7.93
GF Value $6.84
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica Stock Based Compensation?

Oxford BioMedica OXBDF 71 Stock Based Compensation is $6.3 Mil as of Dec. 2025. GuruFocus rates OXBDF with a GF Score™ of 71/100 and a GF Value™ of $6.84 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Oxford BioMedica's Stock Based Compensation for the six months ended in Dec. 2025 was $3.6 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $6.3 Mil.

Oxford BioMedica Stock Based Compensation Related Terms

Oxford BioMedica Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Oxford BioMedica's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioMedica Stock Based Compensation Chart

Oxford BioMedica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.29 7.88 4.45 2.14 6.27

Oxford BioMedica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 0.55 1.59 2.72 3.58
OXBDF
71GF Score
Oxford BioMedica PLC OXBDF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oxford BioMedica Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $6.3 Mil.

What does a Stock Based Compensation of $6.3 Mil mean?
Oxford BioMedica (OXBDF) has a Stock Based Compensation of $6.3 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Oxford BioMedica and its competitors.
Is Oxford BioMedica's Stock Based Compensation too high?
Oxford BioMedica's current Stock Based Compensation is $6.3 Mil. Overall, Oxford BioMedica has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Stock Based Compensation compare to VRTX and REGN?
Oxford BioMedica's Stock Based Compensation of $6.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Oxford BioMedica and its competitors. Oxford BioMedica's current Stock Based Compensation is $6.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.84, compared to a current price of $7.93 — trading 15.9% above its estimated fair value. The current Stock Based Compensation is $6.3 Mil. Oxford BioMedica's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current Stock Based Compensation is $6.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (OXBDF) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of $7.93 is trading 15.9% above its estimated GF Value™ of $6.84. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for OXBDF:

  • Stock Based Compensation: $6.3 Mil
  • GF Value™: $6.84 vs. price of $7.93 (15.9% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBl:UKOXB:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
71GF Score

Get the complete analysis for OXBDF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.93
Price
$6.84
GF Value